Noticeable Stocks to Watch: Auris Medical Holding AG (NASDAQ:EARS), Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

78

Auris Medical Holding AG (NASDAQ:EARS)

Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland.

Auris Medical Holding AG (NASDAQ:EARS)’s Financial Overview

Auris Medical Holding AG (NASDAQ) surged 0% yesterday to close its trading session at $0.56. The company has 1 year Price Target of $4. Auris Medical Holding AG has 52-Week high of $6.6 and 52-Week Low of $0.23. The stock touched its 52-Week High on 6.60 and 52-Week Low on 0.23. The stock traded with the volume of 0 shares yesterday. The firm shows the market capitalization of $3.53 Million.

Auris Medical Holding AG (NASDAQ) reported its last quarterly earnings on 9/29/2017 where the firm reported its Actual EPS of $-1.4/share against the analyst consensus estimate of $-1.65/share. The difference between the actual and expected EPS is $0.25 a share with a surprise factor of 15.2%.

The firm is trading with SMA20 of -12.13 Percent, SMA50 of -17.98 Percent and SMA200 of -43.52 percent. Auris Medical Holding AG has P/S value of 0 while its P/B value stands at 0. Similarly, the company has Return on Assets of 0 percent, Return on Equity of 0 percent and Return on Investment of 0 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 1 analysts offering 12-month price forecasts for Auris Medical Holding AG have a median target of 2.50, with a high estimate of 2.50 and a low estimate of 2.50. The median estimate represents a +347.23% increase from the last price of 0.56.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102, for the management of fibromyalgia syndrome and TNX-105 to treat symptoms of post-traumatic stress disorder. Tonix Pharmaceuticals Holding Corp. is headquartered in New York.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s Financial Outlook

The 4 analysts offering 12-month price forecasts for Tonix Pharmaceuticals Holding Corp have a median target of 1.75, with a high estimate of 3.00 and a low estimate of 0.75. The median estimate represents a -58.53% decrease from the last price of 4.22.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Tonix Pharmaceuticals Holding Corp. has a Consensus Recommendation of 2.2. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock surged 0% and closed its last trading session at $4.22. The company has the market capitalization of $8.06 Million. The stock has 52-week high of $9.6 and 52-Week low of $0.36. The firm touched its 52-Week high on 51.10 and 52-Week low on 3.40. The company has volume of 0 shares. The company has a total of 1.91 Million shares outstanding.

Tonix Pharmaceuticals Holding Corp. (NASDAQ) in the last quarter reported its actual EPS of $-5.7/share where the analyst estimated EPS was $-6.03/share. The difference between the actual and Estimated EPS is $0.33. This shows a surprise factor of 5.5 percent.

The company has YTD performance of -87.77 percent. Beta for Tonix Pharmaceuticals Holding Corp. stands at 1.36 while its ATR (average true range) is 1.16. The company has Weekly Volatility of 30.86%% and Monthly Volatility of 16.68%%.

Tonix Pharmaceuticals Holding Corp. has distance from 20-day Simple Moving Average (SMA20) of -18.95%, Distance from 50-Day Simple Moving Average of -28.05 percent and Distance from 200-Day Simple Moving Average of -81.48%.

The Company currently has ROA (Return on Assets) of -116.8 percent, Return on Equity (ROE) of -131.9 Percent and Return on Investment (ROI) of 0% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.

SHARE